- Home
- MDRR vs PULM Comparison
MDRR vs PULM Comparison
Compare MDRR & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDRR | PULM |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 14.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDRR | PULM |
|---|---|---|
| Price | $12.76 | $4.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 10.4K |
| Earning Date | 11-06-2025 | 10-16-2025 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,098,461.00 | $3,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $134.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.83 | N/A |
| 52 Week Low | $9.55 | $3.90 |
| 52 Week High | $15.00 | $10.40 |
Technical Indicators
Market Signals| Indicator | MDRR | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 47.46 |
| Support Level | $12.75 | $3.95 |
| Resistance Level | $13.71 | $4.94 |
| Average True Range (ATR) | 0.40 | 0.32 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 5.72 | 37.48 |
Price Performance
Historical ComparisonAbout MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).